drugset / Trial / NCT03891849

Macro and Microcirculatory Effects of the Combination of Norepinephrine and Octreotide for the Treatment of Cirrhotic Patients With Hemorrhagic Shock

NCT03891849

NaSingle-groupOpen-labelTreatment

Summary

Octreotide is used to decrease portal pressure of cirrhotic patients admitted for variceal bleeding. When patients are in haemorrhagic shock, the recommended drug to increase arterial pressure is norepinephrine. Microcirculatory effects of octreotide when it is added to noradrenaline has not been investigated yet. The aim of the study is to evaluate the effect of octreotide plus norepinephrine for patient with haemorrhagic shock after variceal bleeding.

Timeline

Start
2021-09-01
Primary completion
2023-05
Completion
2023-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide 25 ug